The results, which will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, include long-term follow-up data from the company’s lentiviral vector (LVV) gene therapies in SCD patients who have a history of vaso-occlusive events (VOEs) and those with beta-thalassemia who require regular red blood cell transfusions.
Affecting approximately 100,000 people in the US, SCD is a life-long, incurable genetic disease that causes red blood cells to take a distinct crescent shape, which can block blood vessels and affect the way oxygen is carried around the body.
